The Pfizer Clinical Research Unit in New Haven is conducting a clinical trial of a study drug for obesity and weight-management. This study will look at the effects of the study drug when taken with and without an additional medication. A subset of Japanese participants may be included in this study.
Obesity is a chronic weight condition that increases the potential risk of other illnesses such as stroke and diabetes. By 2030, it is projected that over a billion people worldwide will be considered obese.
While the scientific and medical community defines obesity as a complex, multifactorial disease requiring prevention and treatment efforts, there is still stigma associated with this condition that impacts patients’ quality of life and access to care. Most people with obesity do not receive any treatment, and diet and lifestyle changes are often not effective or accessible for everyone. Research into additional medication options is therefore essential for patients’ long-term well-being.
Learn how you can make a difference as a healthy volunteer.
Who may participate
When scientists and clinical trial participants work together, the future becomes a little bit brighter.
This study is seeking healthy adult volunteers, meaning that the participants are in overall good, stable health. In addition to the criteria listed, participants must meet the following requirements:
- Willing to take a study drug
- Willing and able to come to our facility in New Haven, CT*
- Japanese participants only: Have 4 Japanese biological grandparents born in Japan
*participants may be eligible to receive a bonus for study travel, ask our staff for details
There are other requirements for participation in this study. The study staff will explain these to you during the screening process.
Do you know someone who may meet these requirements? Refer a friend and you may be eligible to receive a bonus.
Condition
Healthy
Age
18-65 years
Sex
All sexes
Referral bonus
Up to $175
Each clinical study has its own guidelines for who can participate, called eligibility criteria. However, only the research study staff can determine if you qualify to enroll in the study.
What to expect
If this study may be a fit for you, you’ll be invited to a screening visit at our facility in New Haven, CT. If you qualify for the study, there may be a period of up to 28 days before dosing.
If you choose to participate, you will stay at our facility for 25 consecutive overnights. The morning after you check-in, you will receive a single dose of the study drug. Starting about 11 days later, you will receive once-daily doses of an additional medication for 13 days. On the 4th day that you receive this additional medication, you will also receive a dose of the study drug. All doses in this study will be given after breakfast as a tablet or capsule to swallow whole.
Throughout the study, staff will closely monitor your health status and collect data, such as the levels of the study drug in your blood.
This study requires you to stay at the PCRU for the entire duration of each inpatient stay unless you choose to withdraw. You can learn more about what to expect during your participation by browsing our FAQ section.
Required overnight stays
25 consecutive overnights
Long-term follow up
1 phone call
How long is this study?
About 53 days
Compensation
Up to $11,350 upon completion of the study
All of the study procedures will be clearly explained to you during screening and can be viewed in the informed consent form.
We've updated the PCRU Loyalty Program!
We refreshed our Participant Loyalty Program with all-new unique tiered gifts for new and returning participants.
Interested in participating?
Complete and submit this form, and a Pfizer New Haven Clinical Research Unit (PCRU) representative will contact you.
You may also call 1-800-254-6398 and speak with a PCRU representative to learn more.
For Japanese language assistance only, please call 1-833-711-9984.
The personal data gathered here will be collected, processed, and maintained in a confidential manner. Your information will be stored in our research unit’s database. We may use this information to invite you to participate in current and future clinical studies at the PCRU. You will have full access to your records at the Pfizer New Haven Clinical Research Unit and the opportunity to correct them if necessary.